Skip to main content

Table 2 Comparison of background characteristics between the patients with optimal response and suboptimal response

From: Changes in CT morphology can be an independent response marker for patients receiving regorafenib for colorectal liver metastases: retrospective pilot study

  Optimal response Suboptimal response
Age, years
 Median 57 71
 Range 36–67 55–83
Gender
 Male 1 1
 Female 2 6
Primary (colon/rectum)
  0 2
  3 5
RAS (wild/mutant)
 wild 2 3
 mutant 1 4
Performance status
 0 0 2
 1 3 4
 2 0 1
No. of chemotherapy lines
 2 0 1
 3 0 3
 4 2 1
 5 1 2
Cycles of regorafenib
 Median 4 1
 Range 1–15 1–3
Reasons for discontinuation
 Disease progression 2 3
 Toxicity 0 4
Best response in RECIST
 SD 2 2
 PD 1 5
Best change in size
 Median + 16.0% + 25.5%
 Range + 1.4% to + 31.5% −6.2% to + 280.6%
  1. Abbreviations. SD stable disease, PD progressive disease